Laurie Stelzer
CIK 1644348 · Chief Financial Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BUILDING 23, UNIT 105
WALTHAM, MA 02453
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | — | $3.69 | — | $0 | 2 | 2026-06-18 |
| PMVP | Director | — | $1.13 | — | $0 | 6 | 2026-06-05 |
| MBX | Director | — | $50.29 | — | $0 | 2 | 2026-06-05 |
| SYRE | Director | — | $92.91 | — | $0 | 3 | 2026-05-29 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Financial Officer | 102,312 | $58.70 | $6.01M | -$172.2K | 4 | 2023-08-10 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 4 | 2022-06-10 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | EVP & Chief Financial Officer | 28,122 | $99.99 | $2.81M | $0 | 5 | 2022-03-11 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP, Chief Financial Officer | 126,167 | — | — | $344.8K | 22 | 2020-02-24 |
Recent Filings · Page 4 of 5
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-02-04 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +14,844 | -$159.0K | EDGAR |
| 2019-06-17 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +3,467 | -$53.6K | EDGAR |
| 2019-06-06 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-22 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +7,453 | -$66.2K | EDGAR |
| 2019-02-15 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +5,109 | -$44.7K | EDGAR |
| 2019-02-14 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-05 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +14,802 | -$134.1K | EDGAR |
| 2018-06-18 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +3,621 | -$61.9K | EDGAR |
| 2018-02-23 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +7,453 | -$75.9K | EDGAR |
| 2018-02-16 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.